Refactoring pikromycin synthase for the modular biosynthesis of macrolide antibiotics in E. coli.
- 1Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX USA.
Abstract
While engineering modular polyketide synthases (PKSs) using the recently updated module boundary has yielded libraries of triketide-pentaketides, this strategy has not yet been applied to the combinatorial biosynthesis of macrolactones or macrolide antibiotics. Here we developed a two-plasmid system for the construction and expression of PKSs and used it to obtain a refactored pikromycin PKS in Escherichiacoli that produces 49 mg of narbonolide per litre of culture. The replacement, insertion, deletion and mutagenesis of modules enabled access to hexaketide, heptaketide and octaketide derivatives. Supplying enzymes for desosamine biosynthesis and transfer enabled production of narbomycin, pikromycin, YC-17, methymycin and five derivatives thereof. By using native docking domains, knocking out pathways competing with desosamine biosynthesis and supplying the editing thioesterase PikAV, the titre of narbomycin was boosted 58-fold to 37 mg l-1. The second and third modules of the refactored pikromycin synthase were swapped with others to yield three new narbomycin analogues, investigate structure-activity relationships and demonstrate how libraries of macrolide antibiotics can be readily accessed.
Related
- Engineering the effector specificity of the macrolide-sensing transcription factor MphR for the detection of sesquiterpenes
- Emergence of Novel Macrolide-Resistant Mycoplasma pneumoniae Sequence Type 3 Subclades in Children after COVID-19 Pandemic, Taiwan
- Frequency of macrolide resistance-associated mutations in Mycoplasma genitalium: a multicenter molecular analysis based in Brazil.
- Epidemiological Characteristics and Clinical Impact of Macrolide‐Resistant Mycoplasma pneumoniae Infection in Children in Southwest China, 2021–2025
- Optimized alkyne-modified pyridylpiperazine efflux pump inhibitors overcome intrinsic macrolide resistance in multidrug-resistant Klebsiella pneumoniae isolates
BibTeX
@article{miyazawa2026refactoring,
title = {{Refactoring pikromycin synthase for the modular biosynthesis of macrolide antibiotics in E. coli.}},
author = {Takeshi Miyazawa and Ramesh Bista and Adrian T Keatinge-Clay},
journal = {Nature synthesis},
year = {2026},
month = jun,
doi = {10.1038/s44160-026-01108-2},
url = {https://europepmc.org/article/MED/42996680},
note = {CC BY},
}
RIS
TY - JOUR
TI - Refactoring pikromycin synthase for the modular biosynthesis of macrolide antibiotics in E. coli.
AU - Takeshi Miyazawa
AU - Ramesh Bista
AU - Adrian T Keatinge-Clay
PY - 2026
DA - 2026/06/29
JO - Nature synthesis
DO - 10.1038/s44160-026-01108-2
UR - https://europepmc.org/article/MED/42996680
AB - While engineering modular polyketide synthases (PKSs) using the recently updated module boundary has yielded libraries of triketide-pentaketides, this strategy has not yet been applied to the combinatorial biosynthesis of macrolactones or macrolide antibiotics. Here we developed a two-plasmid system for the construction and expression of PKSs and used it to obtain a refactored pikromycin PKS in Escherichiacoli that produces 49 mg of narbonolide per litre of culture. The replacement, insertion, deletion and mutagenesis of modules enabled access to hexaketide, heptaketide and octaketide derivatives. Supplying enzymes for desosamine biosynthesis and transfer enabled production of narbomycin, pikromycin, YC-17, methymycin and five derivatives thereof. By using native docking domains, knocking out pathways competing with desosamine biosynthesis and supplying the editing thioesterase PikAV, the titre of narbomycin was boosted 58-fold to 37 mg l-1. The second and third modules of the refactored pikromycin synthase were swapped with others to yield three new narbomycin analogues, investigate structure-activity relationships and demonstrate how libraries of macrolide antibiotics can be readily accessed.
SN - 2731-0582
ER -